St John’s Wort: Depression Evidence and Serious Interaction Risks

Direct answer

St John's wort may help short-term mild-to-moderate depression, but serious medication interactions and variable products require clinician supervision. Severe or bipolar depression should not be self-treated.

Key takeaways
  • Short-term depression evidence: the Cochrane review included 29 trials and 5,489 patients. Selected extracts improved response versus placebo; comparator findings varied. Fewer withdrawals due to adverse effects versus SSRIs do not establish fewer harms in every category. The review authors disclosed past Schwabe research, speaking or travel support.
  • Evidence is insufficient for severe or bipolar depression. Mild-to-moderate major depressive disorder is included in the positive reviews, but medication changes require a clinician because interaction and undertreatment risks are substantial.
  • Dangerous interactions are the main concern: St John's Wort strongly induces CYP3A4 and P-glycoprotein, reducing effectiveness of oral contraceptives, warfarin, cyclosporine, HIV antiretrovirals, immunosuppressants, some cancer drugs (imatinib, irinotecan), and digoxin.
  • Serotonin syndrome risk when combined with SSRIs, SNRIs, MAOIs, tramadol, triptans, and other serotonergic drugs — can be life-threatening; do not combine.
  • Research regimens vary by extract and indication. A 300 mg three-times-daily schedule used in some studies is not a universal standard or a self-treatment recommendation. (Primary source)

St John’s wort (Hypericum perforatum) has the best evidence for short-term mild-to-moderate depression, but it is not a casual “mood herb” because it can dangerously reduce the effect of many medicines and can combine with antidepressants to raise serotonin to life-threatening levels (NCCIH, Cochrane Review). The biggest safety issue is that many preparations, especially higher-hyperforin extracts, induce CYP3A4 and P-glycoprotein, which can lower blood levels of oral contraceptives, immunosuppressants, HIV medicines, anticoagulants, digoxin, some cancer drugs, and other narrow-therapeutic-index medicines (NCCIH Herb–Drug Interactions, British Journal of Pharmacology review). If you take prescription medication, are pregnant, have bipolar disorder, or are being treated for depression, St John’s wort should be treated as a medicine-level decision, not a self-experiment (EMA herbal monograph, NCCIH).

Evidence summary

ClaimEvidenceSourceFunding / conflict traceStrength
St John’s wort can improve mild-to-moderate depression symptoms.Systematic review of 35 RCTs and 6,993 patients found more responders than placebo, but with substantial heterogeneity.Apaydin et al., Systematic ReviewsUnited States; funded by the Department of Defense Centers of Excellence; authors declared no competing interests; funder reported no role in analysis or publication.Moderate
Severe depression should not be self-treated.The 2016 synthesis found sparse severe-depression research. In the 340-person US trial, neither Hypericum nor sertraline separated from placebo on the primary outcomes; sertraline had a positive secondary CGI result, so assay sensitivity limits the interpretation (systematic review; JAMA trial).US review and trialReview: DoD support/no conflicts declared. Trial: NIH contract, Lichtwer/Pfizer medicine donations and multiple author pharmaceutical research, fee and stock relationships.Limited / clinical care needed
Drug-interaction risk is high and clinically important.NCCIH states St John’s wort is a potent inducer of cytochrome P450 enzymes and intestinal P-glycoprotein; 22 pharmacokinetic trials in a BMJ review mostly showed decreased drug bioavailability.NCCIH Herb–Drug Interactions; Mills et al., BMJNCCIH: U.S. federal public-health source; Mills: Canada/UK/US authorship, funded by Ontario HIV Treatment Network, no competing interests declared.High
Oral contraceptive exposure can fall; pregnancy risk needs separate evidence.Four small combined-pill studies found bleeding and possible ovulation signals, but none measured pregnancies. In one study, 17 women had bleeding in35% of control cycles versus77%/88% with SJW (review; trial). MHRA separately reports suspected pill/implant interactions with pregnancies (safety notice).US review; Swiss trial; UK surveillanceReview: no conflicts declared, separate funding unstated. Swiss trial: partial Senglett Foundation support; named product suppliers do not establish donation terms. Included-study financing varies.Safety concern; studies and surveillance differ
Product composition varies materially.EMA assessment lists multiple constituents, and a 2020 review reports hyperforin in commercial products varying from less than 0.5 mg per unit to 13 mg per unit in one German analysis.EMA assessment report; Nicolussi et al., British Journal of PharmacologyEMA: European regulator; Nicolussi review: Switzerland, three authors employed by an SJW herbal-product manufacturer, so interaction-minimizing claims are downgraded.High for variability; cautious for low-hyperforin claims
Topical minor-wound use has traditional support and limited trial evidence.EMA recognizes preparation-specific traditional use. The 140-woman episiotomy study reported lower pain/redness/edema/ecchymosis, but no significant discharge/dehiscence difference (monograph; original abstract).EU regulator; Iran trialOriginal trial abstract was read; full funding, conflicts and procurement remain unverified.Limited; product/setting specific
Read the practical summary
Medication groupRisk colorMain mechanismWhy it matters
Antidepressants and other serotonergic medicinesAvoid self-combinationPotential serotonin toxicity; mechanism and evidence depend on the specific medicine.NCCIH/EMA warnings support clinical review; not every listed pairing has a controlled SJW trial (NCCIH; EMA).
Cyclosporine, tacrolimus, sirolimus, everolimusRed / avoidCYP3A4 and P-glycoprotein inductionDrug levels can fall and transplant rejection may occur.
HIV antiretrovirals, especially protease inhibitors and non-nucleoside reverse-transcriptase inhibitorsRed / avoidCYP3A4 and P-glycoprotein inductionAntiviral exposure can fall and treatment failure or resistance is possible.
Combined/progestogen-only hormonal contraceptionAvoid SJW; obtain contraceptive adviceLower hormone exposure; pill studies and implant surveillance differ.MHRA advises against co-use for pregnancy prevention; its notice excepted IUDs because it had no data (MHRA).
Warfarin and other anticoagulantsMedicine-specific review / avoid contraindicated combinationsEnzyme or transporter interactions differ by product and medicine.Coumarin anticoagulants are contraindicated for specified EMA preparations. This does not mean every antiplatelet has the same direction of effect (EMA; clopidogrel trial).
Digoxin, cancer medicines, antiepileptics and selected other medicinesPrescriber review requiredDocumented effects, regulatory warnings and theoretical substrate concerns are different evidence types.Do not assume that one mechanism or dose-spacing rule covers all prescriptions (NCCIH; MHRA antiepileptic notice).

What it is

St John’s wort is the common name for Hypericum perforatum L., a yellow-flowering plant native to Europe and introduced to many other regions; the leaves and flowering tops are used in extracts, tinctures, teas, and oils (LiverTox, EMA assessment report). EMA’s herbal inventory lists Hyperici herba as a finalized European herbal assessment with therapeutic areas that include mood disorders, mental stress, gastrointestinal disorders, skin disorders, and minor wounds (EMA product page).

Constituents and proposed activity

The main compound families are naphthodianthrones such as hypericin and pseudohypericin, phloroglucinol derivatives such as hyperforin and adhyperforin, flavonoids such as hyperoside, rutin, isoquercitrin, quercitrin, quercetin, biflavones, procyanidins, tannins, trace xanthones, and volatile-oil components (EMA assessment report, LiverTox). EMA states that dried Hyperici herba contains not less than 0.08% total hypericins expressed as hypericin, while the broader constituent profile varies by raw material, age, extraction solvent, and processing (EMA assessment report). Hyperforin is especially important for drug interactions because it activates the pregnane X receptor pathway that upregulates CYP3A4 and P-glycoprotein, while hypericin is historically used for standardization and is linked to photosensitivity at high exposures (British Journal of Pharmacology review, P-glycoprotein clinical study).

Selected forms & types of St John’s wort

FormWhat it isTypical standardization / variabilityBest-supported useMain downsideVerdict
Standardized dry extract tablets / capsulesConcentrated extract of flowering tops, commonly used in depression trials.Many trials used extracts standardized around 0.3% hypericin; some extracts also report hyperforin, commonly 1–4% in the RAND review, while commercial hyperforin content has varied widely (Apaydin et al., British Journal of Pharmacology review).Mild-to-moderate depression under clinician supervision.Highest concern for clinically meaningful interactions when hyperforin is not low.Most evidence, highest safety burden.
Low-hyperforin quantified extractProduct with stated hyperforin contentThe manufacturer-linked 2020 review argues for low-hyperforin PK risk reduction (review). EMA’s≤1 mg/day statement is narrower: specified traditional oral preparations used no longer than2 weeks, with other enzymes uninvestigated (monograph).Clinician-selected exact preparationThis is not assurance of long-term absence of interactions or serotonergic safety.No general safety guarantee
Whole herb / dried flowering tops / teaComminuted herb infusionEMA’s1.5–2 g/150mL2–3 times/day regimen concerns traditional relief of temporary mental exhaustion, with a 2-week clinical-review boundary (monograph).Preparation-specific traditional useDifferent traditional indications have different regimens; this is not a proven depression schedule.Do not self-dose for depression
TincturesAlcohol/water extract dropsEMA defines traditional1:5 ethanol50–70% and1:10 ethanol45–50% preparations (monograph).Label-specific traditional indicationComposition, alcohol and interaction limits vary.Exact product review needed
Oils / infused oilsVegetable-oil extractsEMA recognizes specified cutaneous preparations for minor inflammation/wounds; some oil preparations also have different traditional oral indications (monograph).Only the product’s authorized route/indicationDo not swallow a topical product or use it on serious wounds; skin reactions/UV precautions matter.Traditional, limited evidence
Combination formulasSJW plus other botanicalsThe black-cohosh/SJW trial randomized89 and analyzed77 completers; the formula cannot isolate SJW (trial).Formula-specific researchJinYang Pharmaceutical support; this is commercial context, not independent ingredient efficacy.No general formula recommendation
Read the practical summary

Standardized extracts have the most clinical trial data but also the greatest need for interaction screening. Low-hyperforin extracts may reduce CYP3A4/P-glycoprotein induction only if the product clearly states low hyperforin and the claim is independently verified. Tinctures and whole-herb teas are less standardized and should not be assumed safer. Oils are primarily topical and should not be taken internally unless a qualified clinician has prescribed a regulated product. Quality products should state extract ratio, plant part, hypericin content, hyperforin content, batch testing, and contraindications.

How it works: mechanism of action

What the body does with it

The antidepressant mechanism is not fully settled, but pharmacology reviews and LiverTox identify hypericin, pseudohypericin, and hyperforin as likely active candidates, with effects across serotonergic, noradrenergic, dopaminergic, GABA, glutamate, inflammatory, and neuroendocrine pathways proposed in the literature (LiverTox, Hypericum traditional uses review). The safety mechanism is clearer than the antidepressant mechanism: hyperforin activates pregnane X receptor, which increases expression of CYP3A4 and P-glycoprotein, leading to faster metabolism or efflux of susceptible medicines and lower systemic exposure (British Journal of Pharmacology review, P-glycoprotein clinical study).

Why form and delivery matter

Different extracts can behave differently because hyperforin, hypericin, and flavonoid concentrations vary widely by extraction method and product, and a German analysis cited in the 2020 pharmacology review found hyperforin from less than 0.5 mg per unit to 13 mg per unit while hypericin varied from 0.1% to 0.3% (British Journal of Pharmacology review). The Cochrane review also warns that hypericum preparations can differ considerably because composition depends on raw material, extraction process, and solvent, which means a trial-tested extract is not automatically interchangeable with a marketplace capsule or tea (Cochrane Review).

Read the practical summary
  1. Some St John’s wort products contain meaningful hyperforin.
  2. Hyperforin activates pregnane X receptor, abbreviated PXR.
  3. PXR activation increases CYP3A4 enzyme expression and P-glycoprotein transporter activity.
  4. CYP3A4 induction increases metabolism of susceptible medicines, while P-glycoprotein induction pumps some medicines back into the gut or out of tissues.
  5. The result can be lower medicine exposure and treatment failure for oral contraceptives, cyclosporine, tacrolimus, antiretrovirals, warfarin, digoxin, statins, chemotherapy medicines, and other substrates.

What works & what doesn’t

Claimed benefitVerdictEvidenceKey caveat
Short-term mild-to-moderate depressionModerate evidence; selected extractsThe 2016 review found more responders than placebo but substantial heterogeneity; antidepressant comparisons were not significantly different (review).No universal product equivalence, long-term guarantee or self-treatment plan.
Severe depressionMIXED / NOT FOR SELF-TREATMENTEvidence is limited, and a U.S. randomized trial in moderately severe major depression found neither Hypericum nor sertraline superior to placebo on primary outcomes (JAMA trial).Severe depression requires clinician-led care because suicide risk and undertreatment risk are serious.
Social anxiety disorderNo benefit demonstrated in a small pilotThe 40-person12-week trial found no significant LSAS benefit (original abstract).One small trial does not establish ineffectiveness for all anxiety disorders; original full disclosures unverified.
Obsessive-compulsive disorderNo benefit demonstrated in this trialA 60-person12-week study found YBOCS change not significantly different versus placebo (original abstract).Specific formulation/short-term result; full funding and product procurement not recovered.
Seasonal affective disorderSJW benefit not established by the cited guidanceNIMH describes light therapy, CBT-SAD and antidepressants; vitaminD results are mixed (treatment guidance).This guidance describes treatment options; it is not a trial of SJW and does not establish SJW efficacy.
Wound healing, topicalMIXED / LIMITEDEMA recognizes traditional topical use for minor wounds, and an episiotomy trial reported improvements in pain and inflammatory signs but not discharge or dehiscence (EMA herbal monograph, Hajhashemi et al. (2018)).Do not apply to serious, infected, deep, surgical, diabetic, or non-healing wounds without medical care.
Menopausal symptomsMIXED / INSUFFICIENTA pilot trial in 47 perimenopausal women showed nonsignificant hot-flash changes favoring St John’s wort and some quality-of-life signals (Menopause trial).Combination trials with black cohosh cannot prove St John’s wort alone works.
ADHDNo benefit demonstrated for the tested productThe 54-child8-week trial was null versus placebo; product content changed during storage and the sample was small (original trial).NIH support, Vital Nutrients active/placebo supply and author pharmaceutical ties disclosed. Do not self-use a different/high-hyperforin product.
Somatoform disordersLimited review-reported evidenceA 2022 narrative review describes a 184-person6-week LI160 trial with a positive response finding (review).Original trial methods/finances and broader replication were not recovered here; no routine treatment recommendation follows.
Read the practical summary

The strongest evidence signal is for mild-to-moderate depression. Severe depression has mixed evidence and should not be self-treated. Topical wound use has traditional support and limited clinical evidence. Menopausal symptoms have pilot-level evidence and cannot be treated as proven. OCD, ADHD, and social anxiety have negative or insufficient trial evidence.

Benefits by claim

Mild-to-moderate depression — Grade B, clinician-supervised only

The best-supported benefit is short-term symptom improvement in mild-to-moderate depression, with the 2016 RAND-linked systematic review finding more responders than placebo and no significant difference from antidepressants in mild and moderate depression (Apaydin et al.). The Cochrane review found hypericum extracts superior to placebo and similarly effective as standard antidepressants in major depression trials, but it also emphasized that country of origin and study precision complicated interpretation and that German-speaking-country trials tended to be more favorable (Cochrane Review). This evidence grade is not “green light for self-treatment” because depression can become severe and because St John’s wort can interact with many medications (NCCIH).

Severe or moderately severe depression — Grade C / mixed

A German manufacturer-funded trial reported WS 5570 was at least as effective as paroxetine and better tolerated in moderate-to-severe depression, but the authors disclosed funding and employment or consultancy relationships with Dr Willmar Schwabe Pharmaceuticals, the manufacturer of WS 5570 (Szegedi et al., BMJ). A large U.S. JAMA trial in 340 adults with major depression found neither St John’s wort nor sertraline significantly better than placebo on the primary outcomes; the authors noted low assay sensitivity as a possible limitation (Hypericum Depression Trial Study Group, JAMA). The practical verdict is that severe depression, suicidal thoughts, bipolar depression, psychosis, postpartum depression, or depression with functional impairment needs clinician-led care, not unsupervised St John’s wort (NCCIH).

Topical wound support — Grade C

EMA’s monograph includes traditional topical use for symptomatic treatment of minor inflammations and minor wounds, which supports traditional external use rather than strong modern proof (EMA herbal monograph). A clinical trial in 140 primiparous women reported that Hypericum perforatum ointment reduced perineal pain, redness, edema, and ecchymosis after episiotomy compared with controls, but discharge and dehiscence did not significantly differ (Hajhashemi et al. (2018)). This does not justify applying St John’s wort oil to deep, infected, diabetic, surgical, or non-healing wounds without medical care.

Risks & selected side effects

St John’s wort side effects are often described as uncommon or mild in depression RCTs, but RCTs were not designed to detect rare serious events, and interaction harms are the dominant safety issue (Apaydin et al., NCCIH). NCCIH lists upset stomach, dry mouth, headache, fatigue, dizziness, confusion, sexual dysfunction, and sensitivity to sunlight as side effects, and it notes that St John’s wort may worsen anxiety in some people because it can act as a stimulant (NCCIH). LiverTox lists gastrointestinal upset, dizziness, confusion, fatigue, anxiety, and photosensitivity, and it emphasizes major interactions through CYP3A4, CYP2C9, and P-glycoprotein rather than convincing clinically apparent acute liver injury from St John’s wort alone (LiverTox).

Side effectFrequency / dose relationshipWhat to doSource
PhotosensitivityDose/product-dependent; precise general frequency unknownAvoid intense UV exposure. A commercial review’s high-dose observations do not establish a universally safe threshold.EMA precaution (monograph); manufacturer-linked review (review).
Gastrointestinal upsetReported; frequency unknown in EMA’s monograph. Historical observational percentages are not general rates. Discuss persistent or severe symptoms.EMA; NCCIH
FatigueReported; frequency unknown in EMA’s monograph. Historical observational percentages are not general rates. Avoid driving when drowsy or dizzy.EMA; NCCIH
Restlessness / anxiety stimulationReported; frequency unknown in EMA’s monograph. Historical observational percentages are not general rates. Seek advice for new or worsening agitation/anxiety.EMA; NCCIH
HeadacheUsually minor and uncommon in general summaries.Stop if severe, new, or associated with blood pressure, fever, confusion, or serotonin-syndrome symptoms.NCCIH
Dry mouthListed by NCCIH; no product-wide rate established.Review troublesome symptoms and the full medicine list. NCCIH
Sexual dysfunctionListed by NCCIH; exact frequency varies by product and trial reporting.Discuss with a clinician; do not add serotonergic drugs to “balance” mood effects.NCCIH
Dizziness / confusionListed by NCCIH and LiverTox.Stop and seek medical advice, especially in older adults or with CNS-active medicines.NCCIH; LiverTox
Mania / worsening psychosisCase reports described by NCCIH; incidence not established.People with bipolar disorder, psychosis or schizophrenia need specialist assessment. NCCIH
Serotonin toxicityPotentially life-threatening with some serotonergic combinations; frequency not established.Avoid self-combination; seek urgent care for concerning symptoms. SJW warning; syndrome symptoms
Read the practical summary

Serotonin syndrome warning signs include agitation, diarrhea, fever, tremor, fast heartbeat, high blood pressure, confusion, and hallucinations. The clinical action is to stop the combination and seek urgent medical care if these symptoms appear after combining St John’s wort with serotonergic medicines.

Selected medicine interactions

St John’s wort is one of the highest-risk botanical supplements for drug interactions because it induces CYP3A4 and P-glycoprotein and because it has serotonergic pharmacodynamic activity (NCCIH Herb–Drug Interactions, Mills et al., BMJ). The interaction can persist after stopping because CYP3A recovery is not immediate; a clinical study found apparent oral midazolam clearance returned to control around 7 days after cessation in 12 healthy men; recovery varied, so this is not a universal safe washout interval, so prescribers often need a washout plan rather than same-day switching (Imai et al.).

Interacts withTypeSeverityMechanismClinical action
SSRIs such as sertraline, fluoxetine, paroxetine, citalopram, escitalopramPharmacodynamicSERIOUS / avoidAdditive serotonergic effects can raise serotonin to potentially life-threatening levels.Do not combine unless a psychiatrist explicitly supervises; urgent care for serotonin-syndrome symptoms (NCCIH).
SNRIs and other serotonergic medicinesPotential pharmacodynamic interactionAvoid self-combinationSome serotonergic combinations can produce severe toxicity; the source is not a controlled trial of every named SNRI.Obtain a specific prescriber plan (NCCIH; EMA).
MAO inhibitors and other serotonergic medicinesPotential pharmacodynamic interactionAvoid self-combinationGeneral serotonin-toxicity guidance and EMA warnings require medicine-specific review.Do not infer a safe combination or washout from this guide (MedlinePlus; EMA).
Tricyclic antidepressantsMedicine-specific PK / pharmacodynamic concernsPrescriber reviewThe PK review includes an amitriptyline study; this does not establish every tricyclic has the same interaction or magnitude.Review the exact medicine; serotonergic combinations have additional precautions (PK review; EMA).
Hormonal contraceptionPK / pharmacovigilanceAvoid SJW; seek contraceptive advicePill trials show lower exposure, bleeding and possible ovulation; MHRA separately reports suspected pregnancies including implants.MHRA advises against SJW with hormonal contraception for pregnancy prevention; its IUD exception reflects absent data in that notice (review; trial; MHRA).
Warfarin / coumarin anticoagulantsPKContraindicated for specified EMA preparationsEnzyme induction can reduce anticoagulant effect; stopping SJW can also change exposure.Do not add SJW or self-adjust warfarin; the prescriber must review exposure changes (EMA; LiverTox).
DOACs and clopidogrelMedicine-specific PK / platelet effectsSpecialist reviewCYP/Pgp concerns do not prove every DOAC pairing. Clopidogrel is different: a small14-day study found greater platelet inhibition, rather than reduced action.Clinical outcomes and a safe regimen were not established; obtain medicine-specific guidance (clopidogrel abstract; general interaction chapter).
DigoxinPharmacokineticSERIOUSP-glycoprotein induction can reduce digoxin exposure; NCCIH lists documented clinically significant interaction.Avoid or monitor digoxin levels and symptoms under prescriber care (NCCIH Herb–Drug Interactions, P-gp study).
CyclosporinePharmacokineticCRITICAL / avoidCYP3A4 and P-gp induction can lower levels and has been linked to transplant rejection.Contraindicated unless transplant team explicitly directs; never self-use after transplant (NCCIH, cyclosporine study).
Tacrolimus, sirolimus, everolimus, and other immunosuppressantsPharmacokineticCRITICAL / avoidEMA lists systemic tacrolimus, sirolimus, everolimus, and cyclosporine among contraindicated combinations for relevant preparations.Do not combine; consult transplant specialist before any botanical supplement (EMA monograph).
HIV medicinesPKAvoid contraindicated combinationsNCCIH names indinavir; EMA lists protease inhibitors and non-nucleoside reverse-transcriptase inhibitors for relevant preparations.Not every antiretroviral class has the same metabolism or clinical evidence. The HIV team must review the exact regimen (NCCIH; EMA).
TheophyllinePharmacokineticHIGHEnzyme induction may reduce exposure to narrow-therapeutic-index respiratory medicine.Avoid unsupervised use; monitor levels and symptoms if a prescriber permits (Mills et al., BMJ).
Antiepileptic medicinesRegulatory warning; mechanism variesAvoid co-useMHRA extended its warning after seizure worsening reported with levetiracetam, lamotrigine and clobazam, including mechanisms beyond known CYP induction.The notice advises against SJW with all antiepileptics; this is pharmacovigilance guidance, not a mechanism trial for each medicine (MHRA).
Triptans and other serotonergic agentsPotential pharmacodynamic interactionPrescriber review / avoid self-combinationMedlinePlus identifies triptans as serotonergic exposures; EMA advises caution with serotonergic SJW combinations.No controlled pairing trial is established for every listed triptan (syndrome guidance; EMA).
Simvastatin; other statins need separate reviewPK / observed lipid effectPrescriber reviewA 24-person crossover found higher LDL and total cholesterol during SJW plus simvastatin.This study does not verify every statin, an alternative drug choice or a dosing workaround (trial).
Calcium-channel blockers / other CYP substratesPotential PK concernExact-drug reviewGeneral enzyme-induction guidance does not establish an interaction for every named blocker.Ask the prescriber/pharmacist about the exact product and medicine; do not infer a safe schedule from a class name (NCCIH interactions).
Chemotherapy and targeted cancer medicines including irinotecan and imatinibPharmacokineticCRITICAL / avoidEMA lists irinotecan, imatinib, and other cytostatic agents metabolized by CYP3A4, CYP2B6, CYP2C9, CYP2C19, or transported by P-gp as contraindicated combinations for relevant preparations.Do not combine; oncology team must review every supplement (EMA monograph, NCCIH).
Thyroid medicine or other prescriptionsUnresolved in the sources checkedMedicine-specific reviewThis article has not established a direct levothyroxine interaction, magnitude or dose-spacing rule.Ask the treating clinician about the exact medicine; spacing doses is not a proven solution to enzyme induction.
Medicines that increase light sensitivityPotential added skin riskClinical review / UV precautionEMA/NCCIH advise avoiding intense UV exposure; the source does not test every named photosensitizing pairing.Review the exact medicine and seek care for severe skin reactions (EMA; NCCIH).
Benzodiazepines, sedatives, oxycodone, and other CYP3A substratesPharmacokineticHIGHNCCIH lists benzodiazepines and oxycodone among documented or clinically important interaction concerns, mainly through reduced drug exposure.Prescriber review required; monitor sedation, withdrawal symptoms, pain control, and therapeutic failure (NCCIH, NCCIH Herb–Drug Interactions).

Clinical action rule: St John’s wort should be entered into the medication list like a prescription drug. The safest default is avoid when the other medicine prevents pregnancy, organ rejection, HIV progression, blood clots, seizures, arrhythmia, cancer progression, severe depression, or hospitalization.

Who should avoid it: contraindications

Anyone taking prescriptions needs a medicine-specific review before starting or stopping SJW (NCCIH). EMA does not recommend use during pregnancy/lactation; its age boundaries differ: oral use under18 and traditional cutaneous use under12 are not recommended (monograph). NCCIH describes case reports of worsening psychotic symptoms in bipolar disorder or schizophrenia (NCCIH). Tell the surgical/anesthesia team about use rather than assuming a dose-spacing or fixed washout rule.

Dosage & how to take

Trial doses are preparation-specific: the Steiner-funded STEI300 study used 350 mg three times daily, while Schwabe-funded WS5570 research tested 600/1200 mg/day (STEI300 trial; WS5570 trial). EMA provides different dose/indication schedules for defined extracts; its tea regimen is traditional temporary mental exhaustion, not generic depression treatment (monograph). These are research/regulatory descriptions, not an instruction to self-dose. Same-mass products can deliver different constituents (manufacturer-linked composition review).

Independent evidence, funding & conflict review

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

9 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

The Cochrane review found more favorable results in German-speaking trials and smaller/less precise studies. It discusses several possible explanations; neither prescribing culture nor national regulation was shown to cause the difference (review). The US trial had null primary findings, commercial medicine donations and multiple author ties (trial). Reviews, original studies and regulator warnings serve different purposes; the disclosures below apply to each source, not automatically to every study it cites.

SourceCountry / institutionEvidence typeFunding / conflictsIndependence ratingCredibility rankHow used in this article
Apaydin 2016US RAND-linked review35 studies/6993 peopleDoD Centers of Excellence support; no conflicts declared; no funder data/analysis/writing/publication role. Included-trial finance not exhaustively traced.Publicly funded review; underlying trials varyModerate clinical certainty; high heterogeneityMain short-term efficacy synthesis
Linde 2008 CochraneGermany-affiliated authors29 trials/5489 peopleInternal TUM/Freiburg support; no external support supplied. Berner reported Schwabe research grants/conference fees; Linde/Kriston Schwabe travel reimbursement.Manufacturer relationships disclosedMethodological context; downgraded for strict independenceResponse/withdrawal/country findings with limits
JAMA 2002 HypericumtrialUS12academic/community sites340-person8-week RCTNCCAM/NIMH contractN01MH70007; Lichtwer/Pfizer medicine donations. Multiple authors reported pharmaceutical research, fees, consulting or stock interests.Public contract plus commercial supply/author tiesNull-primary/assay-sensitivity contextNot independent proof of a universal severe-depression result
Szegedi et al., BMJ 2005 WS 5570 trialGermany.Moderate-to-severe depression RCT versus paroxetine.Funded by Dr Willmar Schwabe Pharmaceuticals; employees and consultants disclosed.ConflictedModerate; useful but downgraded.Included as context, not decisive proof.
Kasper et al., WS 5570 placebo trialAustria/Germany.Placebo-controlled RCT.Funded by Dr Willmar Schwabe Pharmaceuticals; employees, consultants, and medical-writing support disclosed.ConflictedModerate; useful but downgraded.Included for dose context and conflict transparency.
Mills 2004 PKreviewCanada/UK/US authorship22 small PK studiesOntario HIV Treatment Network; no conflicts declared. Underlying studies’ procurement/finance not all traced.Declared public/charitable support; trial level variesDirect PK synthesis; small heterogeneous studiesInteraction exposure evidence; not universal clinical outcomes
Nicolussi et al., 2020 interaction reviewSwitzerland.Pharmacology review.Three authors were employees of a manufacturer of an SJW herbal medicinal product.ConflictedModerate; mechanistic details useful, low-hyperforin safety claims downgraded.Used for product-variability and mechanism, with conflict warning.
NCCIHdepressionguidanceUS federal agencyPublic safety/clinical summary; updated 2017Named reviewers; page-specific contributor finance and every underlying study not exhaustively disclosed here.Official guidance sourceSafety communication; historical summary dateDrug and psychiatric cautions, not a product endorsement
EMAHMPC 2022 monographEU regulatorDefined preparation/indication monographConsultation/process documented. Every assessor’s personal and underlying trial relationships not traced here.Official regulator sourcePreparation-specific regulatory guidanceAge, duration, route, contraindication and traditional-use distinctions
Read the practical summary

Systematic reviews from Cochrane, RAND-linked authors and BMJ receive weight for their methods, while funding and conflicts are assessed separately. Manufacturer-funded trials from Schwabe and Steiner are useful but downgraded because the sponsor benefits from positive findings. A 2020 low-hyperforin interaction review is useful for mechanism and product variability but its low-interaction conclusion is downgraded because three authors worked for an SJW herbal-product manufacturer. The editorial bottom line is that European positive evidence matters, but interaction safety gets the highest weight. (Primary source)

For deeper, evidence-graded context on the conditions St John's wort is most often used for, see Pure City Research's condition guides:

Frequently Asked Questions

Is St John’s wort safe to take with antidepressants?

No, not without specialist supervision. NCCIH warns that combining St John’s wort with certain antidepressants can cause a potentially life-threatening serotonin increase, so SSRIs, SNRIs, MAOIs, tricyclics, and other serotonergic drugs should generally be treated as avoid combinations (NCCIH).

Does St John’s wort really work for depression?

It has moderate evidence for mild-to-moderate depression, but results vary by study setting, extract, and severity. A 2016 systematic review found St John’s wort superior to placebo and not significantly different from antidepressant medication in mild and moderate depression, while severe-depression evidence remains weaker (Apaydin et al.).

Can St John’s wort make birth control fail?

Yes, it can reduce hormonal contraceptive exposure and has been associated with breakthrough bleeding and concern for reduced contraceptive efficacy. A systematic review of four small combined-oral-contraceptive studies found increased breakthrough bleeding and possible ovulation signals, but none measured actual pregnancy rates (Berry-Bibee et al.).

How long do St John’s wort interactions last after stopping?

Interaction intensity may decline over days rather than immediately. A CYP3A recovery study found midazolam oral clearance returned to control around 7 days after St John’s wort cessation in 12 healthy men; the result does not define a safe interval for every medicine or person, so medication changes should be planned with a prescriber rather than handled as a same-day switch (Imai et al.).

Is topical St John’s wort oil safer than capsules?

Topical and oral products have different routes and indications. Do not swallow a topical oil or assume its systemic interaction risk has been quantified. EMA supports traditional topical use for minor inflammation and minor wounds, but serious, infected, deep, diabetic, surgical, or non-healing wounds require medical care (EMA herbal monograph).

What is the difference between hypericin and hyperforin?

Hypericin is a naphthodianthrone often used for standardization and associated with photosensitivity at higher exposure, while hyperforin is a phloroglucinol derivative strongly tied to PXR activation and CYP3A4/P-glycoprotein induction. EMA lists both as important constituents, and pharmacology reviews emphasize hyperforin as a key interaction driver (EMA assessment report, British Journal of Pharmacology review).

Availability and legal classification vary by country and by product. Do not assume an over-the-counter supplement and an authorized herbal medicine have the same status; check the local regulator's current product record or a pharmacist. Ireland's HPRA provides a medicines database (HPRA medicines database).

Who should never self-start St John’s wort?

People taking prescription medicines, oral contraceptives, anticoagulants, transplant drugs, HIV medicines, cancer medicines, antidepressants, triptans, anticonvulsants, digoxin, or multiple chronic medicines should not self-start it. Pregnant or lactating people, children and adolescents, people with bipolar disorder, mania, psychosis, schizophrenia, severe depression, or suicidal thoughts should avoid unsupervised use (NCCIH, EMA herbal monograph).

Sources

  1. NCCIH — St. John’s Wort and Depression: In Depth
  2. NCCIH — Herb–Drug Interactions
  3. EMA — Hyperici herba product page
  4. EMA/HMPC — European Union herbal monograph on Hypericum perforatum L., herba
  5. EMA/HMPC — Final assessment report on Hypericum perforatum L., herba
  6. Apaydin EA et al. A systematic review of St. John’s wort for major depressive disorder. Systematic Reviews. 2016
  7. Linde K et al. St John’s wort for major depression. Cochrane Database of Systematic Reviews. 2008
  8. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum in major depressive disorder. JAMA. 2002
  9. Mills E et al. Interaction of St John’s wort with conventional drugs: systematic review of clinical trials. BMJ. 2004
  10. Nicolussi S et al. Clinical relevance of St. John’s wort drug interactions revisited. British Journal of Pharmacology. 2020
  11. Berry-Bibee EN et al. Co-administration of St. John’s wort and hormonal contraceptives: a systematic review. Contraception. 2016
  12. Pfrunder A et al. Interaction of St John’s wort with low-dose oral contraceptive therapy. British Journal of Clinical Pharmacology. 2003
  13. LiverTox — St. John’s Wort
  14. Kobak KA et al. St John’s wort versus placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology. 2005
  15. Kobak KA et al. St. John’s wort versus placebo in social phobia. Journal of Clinical Psychopharmacology. 2005
  16. Weber W et al. Hypericum perforatum for ADHD in children and adolescents. JAMA. 2008
  17. Hajhashemi M, Ghanbari Z, Movahedi M, Rafieian M, Keivani A, Haghollahi F. The effect of Achillea millefolium and Hypericum perforatum ointments on episiotomy wound healing in primiparous women. 2018. Research record
  18. Effects of Hypericum perforatum on hot flashes and quality of life in perimenopausal women. Menopause. 2009
  19. Imai H et al. Recovery time-course of CYP3A after induction by St John’s wort. British Journal of Clinical Pharmacology. 2008
  20. Hennessy M et al. St John’s wort increases expression of P-glycoprotein. British Journal of Clinical Pharmacology. 2002
  21. Eggertsen R et al. Effects of St John’s wort and simvastatin treatment. Scandinavian Journal of Primary Health Care. 2007
  22. Kasper S et al. WS 5570 compared to placebo in major depression. BMC Medicine. 2006
  23. Szegedi A et al. WS 5570 versus paroxetine in moderate to severe depression. BMJ. 2005
  24. Philipp M et al. Hypericum extract versus imipramine or placebo. BMJ. 1999
  25. Clauson KA et al. Clinically relevant safety issues associated with St. John’s wort product labels. BMC Complementary and Alternative Medicine. 2008
  26. Perloff MD, von Moltke LL, Störmer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. 2001. Research record
  27. Wenk M et al. Effect of St John’s wort on CYP activities in healthy males and females. British Journal of Clinical Pharmacology. 2004
  28. Chung 2007. Black-cohosh/SJW combination trial; JinYang Pharmaceutical support. Original study
  29. 2022 review of Hypericum traditional uses and clinical aspects. Somatoform finding is review-reported. Review
  30. Lau 2011. SJW effect on platelet inhibition in clopidogrel hyporesponders. Original abstract
  31. Bauer 2003. SJW/cyclosporine pharmacokinetics in renal transplant recipients. Original study
  32. MHRA. SJW and antiepileptics; historical2007 warning. Official notice
  33. NIMH. Seasonal affective disorder; revised 2023. Treatment guidance
  34. MedlinePlus/ADAM. Serotonin syndrome; reviewed 2026. Clinical summary
  35. MHRA. SJW and hormonal contraception including implants;2014. Official notice
  • Medical disclosure: This is educational content, not medical advice. St John’s wort has clinically serious interaction risks; consult a qualified healthcare professional before using it, especially if you take any medication or have depression symptoms.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.